Prodrug of vitamin D3
Related Products
Active Metabolite(s)
71820Calcitriol
Isomer(s)
342003-epi-25-hydroxy Vitamin D3
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

1-hydroxy Vitamin D3

Item No. 12082

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
5-[2E-[(3aS)-1R-[1R,5-dimethylhexyl]octahydro-7aR-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1R,3R-cyclohexanediol
CAS Number
41294-56-8
Synonyms
  • Alfacalcidol
  • α-Calcidol
  • Etalpha
  • 1-hydroxy Cholecalciferol
  • Tevabone
Molecular Formula
C27H44O2
Formula Weight
400.6
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 20 mg/mlDMSO: 20 mg/mlEthanol: 20 mg/mlEthanol:PBS (pH 7.2) (1:3): 0.30 mg/ml
λmax
213, 265 nm
SMILES
C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCCC(C)C)([H])/C(CCC1)=C/C=C3C[C@@H](O)C[C@H](O)C/3=C
InChi Code
InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1
InChi Key
OFHCOWSQAMBJIW-AVJTYSNKSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $41

    Add

    5 mg

    $157

    Add

    10 mg

    $258

    Add
    Product Description

    1-hydroxy Vitamin D3 is a synthetic prodrug which is converted by cytochrome P450 isoforms to the vitamin D receptor agonist 1,25-dihydroxy vitamin D3 in vivo.1,2 Such prodrugs are effective in suppressing the synthesis and secretion of parathyroid hormone in secondary hyperparathyroidism, an action which requires the vitamin D receptor.3,2,4 1-hydroxy Vitamin D3 supports bone growth both in postmenopausal women and in glucocorticoid-induced osteoporosis.5,6 It also provides renal and cardiovascular protection during chronic kidney disease.7,8

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Upton, R.A., Knutson, J.C., Bishop, C.W., et al. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrol. Dial. Transplant 18, 750-758 (2003).

    2. Brown, A.J., Dusso, A.S., and Slatopolsky, E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol. Dial. Transplant. 17(Suppl), 10-19 (2002).

    3. Frazao, J.M., Chesney, R.W., Coburn, J.W., et al. Intermittent oral 1α-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol. Dial. Transplant 13, 68-72 (1998).

    4. Ritter, C.S., and Brown, A.J. Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. J. Mol. Endocrinol. 46(2), 63-66 (2011).

    5. Nuti, R., Bianchi, G., Brandi, M.L., et al. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol. Int. 26, 445-453 (2006).

    6. Pereira, R.M.R., de Carvalho, J.F., Paula, A.P., et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev. Bras. Reumatol. 52(4), 580-593 (2012).

    7. Gravellone, L., Rizzo, M.A., Martina, V., et al. Vitamin D receptor activators and clinical outcomes in chronic kidney disease. Int. J. Nephrol. 419524 (2011).

    8. Jorgensen, H.S., Winther, S., Povlsen, J.V., et al. Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: A retrospective single center study. BMC Nephrol. 13(1), (2012).